Taken together, these results demonstrate that ZDHHC3-high tumors harbor a higher TP53 and KRAS mutation rate, which may cooperatively contribute to disease progression and prognosis status in pancreatic cancer. This evidence concerns the gene TP53 and familial pancreatic carcinoma.